Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The Antiviral Drugs market in Guinea has been witnessing significant growth in recent years due to various factors.
Customer preferences: Customers in Guinea have been increasingly demanding antiviral drugs due to the rise in viral infections and diseases. The demand is particularly high for drugs that are effective against diseases such as HIV, hepatitis B and C, and influenza. Patients are willing to pay a premium for drugs that are effective and have fewer side effects.
Trends in the market: One of the key trends in the Antiviral Drugs market in Guinea is the increasing use of generic drugs. The high cost of branded drugs has made it difficult for many patients to afford treatment. As a result, many patients have turned to generic drugs, which are cheaper and more widely available. This trend is expected to continue in the coming years as more generic drugs become available in the market.Another trend in the market is the increasing focus on research and development. Pharmaceutical companies are investing heavily in R&D to develop new drugs that are more effective and have fewer side effects. This is expected to lead to the introduction of new drugs in the market, which will further drive growth in the Antiviral Drugs market in Guinea.
Local special circumstances: Guinea has a high prevalence of infectious diseases such as HIV, hepatitis B and C, and influenza. This has led to a high demand for antiviral drugs in the country. The government has taken several initiatives to improve access to healthcare, which has further boosted the demand for antiviral drugs.
Underlying macroeconomic factors: The Antiviral Drugs market in Guinea is also influenced by macroeconomic factors such as GDP growth and healthcare spending. The country has been experiencing steady economic growth in recent years, which has led to an increase in healthcare spending. This has created a favorable environment for the growth of the Antiviral Drugs market in Guinea.In conclusion, the Antiviral Drugs market in Guinea is witnessing significant growth due to the rising demand for drugs that are effective against viral infections and diseases. The increasing use of generic drugs and focus on research and development are expected to further drive growth in the market. The high prevalence of infectious diseases, government initiatives to improve access to healthcare, and favorable macroeconomic factors are also contributing to the growth of the market.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights